January 24, 2023 09:00 AM ESTUpdated February 7, 09:34 AM
R&D

#JPM23: Fire­side chat with Ei­sai's Ivan Che­ung

Drew Armstrong

Executive Editor

Less than a week af­ter Ei­sai and Bio­gen won ac­cel­er­at­ed ap­proval from the FDA for their Alzheimer’s drug lecanemab, Ex­ec­u­tive Ed­i­tor Drew Arm­strong spoke one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

A service from the Financial Times